Who are Zoladex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trelstar, Vantas, Synarel, Zoladex, Lupron, Lupron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/goserelin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Zoladex — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zoladex (goserelin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin Releasing Hormone Receptor Agonist. Area: Oncology.

marketed Gonadotropin Releasing Hormone Receptor Agonist pituitary gonadotropin secretion Oncology Live · refreshed every 30 min

Target snapshot

Zoladex (goserelin) — Tersera. ZOLADEX inhibits pituitary gonadotropin secretion, leading to regression or inhibition of hormonally sensitive tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zoladex TARGET	goserelin	Tersera	marketed	Gonadotropin Releasing Hormone Receptor Agonist	pituitary gonadotropin secretion	1989-01-01
Trelstar	triptorelin	Verity	marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	2000-01-01
Vantas	HISTRELIN		marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1991-01-01
Synarel	NAFARELIN	Pfizer	marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1990-01-01
Zoladex	GOSERELIN ACETATE	Tersera	marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1989-01-01
Lupron	leuprolide	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1985-01-01
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (Gonadotropin Releasing Hormone Receptor Agonist class)

Accord Healthcare S.L.U. · 2 drugs in this class
Tersera · 2 drugs in this class
· 1 drug in this class
Pfizer · 1 drug in this class
Verity · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zoladex — Competitive Intelligence Brief. https://druglandscape.com/ci/goserelin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing